Skip to content

Efficacy, Safety and Mechanism of Modified Xianyaoyin in Patients with Mild to Moderate Hypertriglyceridemia: A Study Protocol for a Multicenter and Randomized Controlled Trial

Efficacy, Safety and Mechanism of Modified Xianyaoyin in Patients with Mild to Moderate Hypertriglyceridemia: A Study Protocol for a Multicenter and Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006417
Enrollment
Unknown
Registered
2022-08-01
Start date
2022-07-18
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Interventions

CONTROL:treated with placebo, twice a day, one bag in the morning and one bag in the evening, taken with water, and the course of treatment is 12 weeks.
TEST:treated with modified Xianyaoyin granules, twice a day, one bag in the morning and one bag in the evening, taken with water, and the course of treatment is 12 weeks.
TEST:lifestyle
CONTROL:lifestyle
01020000

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Aged from 18 to 65 years old. (2)1.7=TG<5.7mmol/l, LDL-C<4.9mmol/l, TC<7.2mmol/l. (3)Meet the diagnostic criteria of TCM syndrome of phlegm and blood stasis based on the Guiding Principles for Clinical Research of New Traditional Chinese Medicine (2002). Main symptoms: obesity, heaviness of the head, vomiting of phlegm and saliva, numbness and lassitude of limbs, and chest distress. Secondary symptoms: palpitation, insomnia, anorexia and relentlessness. Tongue & pulse: enlarged tongue with slippery/slimy coating, ecchymosis and petechia. Wiry or rough pulse. Patients with 1 main symptom / 2 secondary symptoms and above tongue and pulse can be diagnosed as phlegm and blood stasis. (4)Inform consent.

Exclusion criteria

Exclusion criteria: (1)Taking other drugs or measures with triglyceride-lowering effect within 3 months, including food supplements and additives. (2)Secondary hypertriglyceridemia, drug-induced hypertriglyceridemia, homozygous hypercholesterolemia. (3)Suspected allergy to the test drug or any of its components. (4)Alanine aminotransferase(ALT) and / or aspartate aminotransferase(AST) = 3 times of the upper limit of normal(ULN) and creatinine(CREA) = 1.5×ULN. (5)Combined with coronary heart disease or chronic heart failure. New York Heart Association (NYHA) class III or IV. History of acute coronary syndrome, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). (6)Diabetes, hypothyroidism, systolic blood pressure (SBP) = 160mmHg or diastolic blood pressure (DBP) = 100mmHg. (7)Pregnancy or lactation. Females with pregnancy plans or reluctant to take contraceptive measures are also excluded. (8)Suffered from severe trauma or surgery within 3 months, such as gastrointestinal bleeding. (9)Body mass index = 30. (10)Weight fluctuation = 3kg in recent 6 months; (11)History of mental illness, alcohol / drug dependence or malignant tumor. (12)Got COVID-19 vaccine or participated in other clinical trials within 3 months. (13)Not suitable to be enrolled after evaluation by the investigators.

Design outcomes

Primary

MeasureTime frame
fasting triglycerides;

Secondary

MeasureTime frame
fasting low-density lipoprotein cholesterol;fasting high-density lipoprotein cholesterol;body mass index;fasting total cholesterol;TCM Syndromes Scale;lipoprotein a;degree of fatty liver;

Countries

China

Contacts

Public ContactLongtao Liu

Xiyuan Hospital, China Academy of Chinese Medical Sciences

liulongtao1976@126.com13681444817

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026